JPS6236483B2 - - Google Patents
Info
- Publication number
- JPS6236483B2 JPS6236483B2 JP55019932A JP1993280A JPS6236483B2 JP S6236483 B2 JPS6236483 B2 JP S6236483B2 JP 55019932 A JP55019932 A JP 55019932A JP 1993280 A JP1993280 A JP 1993280A JP S6236483 B2 JPS6236483 B2 JP S6236483B2
- Authority
- JP
- Japan
- Prior art keywords
- piglets
- blood cells
- transfer factor
- white blood
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000000265 leukocyte Anatomy 0.000 claims description 22
- 108010074506 Transfer Factor Proteins 0.000 claims description 17
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- 241000282887 Suidae Species 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 description 11
- 241000282898 Sus scrofa Species 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QFJAZXGJBIMYLJ-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;ethane-1,2-diamine Chemical compound NCCN.OC(=O)C(O)C(O)C(O)=O QFJAZXGJBIMYLJ-UHFFFAOYSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1993280A JPS56115720A (en) | 1980-02-18 | 1980-02-18 | Prophylactic agent for pigling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1993280A JPS56115720A (en) | 1980-02-18 | 1980-02-18 | Prophylactic agent for pigling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56115720A JPS56115720A (en) | 1981-09-11 |
| JPS6236483B2 true JPS6236483B2 (en]) | 1987-08-07 |
Family
ID=12012984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1993280A Granted JPS56115720A (en) | 1980-02-18 | 1980-02-18 | Prophylactic agent for pigling |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56115720A (en]) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6257974U (en]) * | 1985-09-30 | 1987-04-10 | ||
| JPS63239612A (ja) * | 1987-03-26 | 1988-10-05 | Fuji Photo Film Co Ltd | 磁気ヘツドのアジマス調整方法及びその機構 |
| JPS63181162U (en]) * | 1987-05-11 | 1988-11-22 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103892166B (zh) * | 2014-04-11 | 2016-11-23 | 江西德泰医药生物技术有限公司 | 一种多肽因子和中草药提取物制备保健食品的方法 |
-
1980
- 1980-02-18 JP JP1993280A patent/JPS56115720A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6257974U (en]) * | 1985-09-30 | 1987-04-10 | ||
| JPS63239612A (ja) * | 1987-03-26 | 1988-10-05 | Fuji Photo Film Co Ltd | 磁気ヘツドのアジマス調整方法及びその機構 |
| JPS63181162U (en]) * | 1987-05-11 | 1988-11-22 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56115720A (en) | 1981-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Griel Jr et al. | Clinical and clinico-pathological effects of Escherichia coli endotoxin in mature cattle | |
| Schulkind et al. | Transfer factor in the treatment of a case of chronic mucocutaneous candidiasis | |
| Wexler et al. | III. The Fate of Citrate in Erythroblastotic Infants Treated with Exchange Transfusion | |
| US20080299212A1 (en) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum | |
| JPH0761956B2 (ja) | 静注可能な免疫グロブリン | |
| JP2834244B2 (ja) | 抗炎症因子、その単離方法、およびその使用 | |
| JPS5920229A (ja) | 強化されたオプソニン活性を有する組成物 | |
| US3917818A (en) | Treatment of mastitis in cows, the product for this treatment and to the production of said product | |
| BECKER et al. | Fatal anaphylaxis after intramuscular iron-dextran | |
| EP0484148A1 (en) | A method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis and thus formulated medicines | |
| JPH08502718A (ja) | 抗炎症因子、その単離方法、および用途 | |
| DK158334B (da) | Fremgangsmaade til fremstilling af polypeptidfraktioner fra muslinger | |
| JPS6236483B2 (en]) | ||
| Jadhav et al. | Antivenin production in India | |
| Melnick et al. | Development of Incompatibilities in Dogs by Repeated Infusions of Red Blood Cells. | |
| Eichenwald | Experimental toxoplasmosis. II. Effect of sulfadiazine and antiserum on congenital toxoplasmosis in mice | |
| Donta et al. | Cephalosporin-associated colitis and Clostridium difficile | |
| JPH06340549A (ja) | ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法 | |
| US3591677A (en) | Allergenic extract and process for preparing same | |
| JP2672303B2 (ja) | 馬用感染予防治療剤 | |
| EP0065395B1 (en) | Improved chymopapain and method for its production and use | |
| Raziuddin et al. | Binding of bacterial endotoxin (LPS) to encephalitogenic myelin basic protein and modulation of characteristic biologic activities of LPS. | |
| JP2003507334A (ja) | 血漿代用組成物 | |
| US3002888A (en) | Lipid-mobilizing composition | |
| Holdsworth et al. | Absorption of vitamin B12 from the rat intestine |